Ultragenyx Pharmaceutical (RARE) Misses Q3 EPS by 4c

Ultragenyx Pharmaceutical (NASDAQ: RARE) reported Q3 EPS of ($0.50), $0.04 worse than the analyst estimate of ($0.46).

For earnings history and earnings-related data on Ultragenyx Pharmaceutical (RARE) click here.

You May Also Be Interested In

• HP shares slide as tech giant forecasts 2027 PC market slump
• Standard Uranium extends private placement closing date to October 18
• Ultragenyx Pharma (RARE) PT Raised to $39 at Canaccord